UB Paderborn / Katalog / Suche / in CDI

Sortiert nach

Einfacher Volltextzugriff von (fast) überall

Installieren Sie die LibKey Nomad-Browsererweiterung und erhalten Sie von vielen Webseiten einfachen Zugriff auf lizenzierte Volltexte oder Open Access Publikationen. Mehr erfahren...

Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

Neurology, 2007-07, Vol.69 (1), p.91-102

2007

Volltextzugriff (PDF)

Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology

Neurology, 2011-01, Vol.76 (1), p.94-99

2011

Volltextzugriff (PDF)

Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology

Neurology, 2010-11, Vol.75 (22), p.2021-2027

2010

Volltextzugriff (PDF)

Changing Motor Synergies in Chronic Stroke

Journal of neurophysiology, 2007-08, Vol.98 (2), p.757-768

2007

Volltextzugriff (PDF)

Learning, Not Adaptation, Characterizes Stroke Motor Recovery: Evidence From Kinematic Changes Induced by Robot-Assisted Therapy in Trained and Untrained Task in the Same Workspace

IEEE transactions on neural systems and rehabilitation engineering, 2012-01, Vol.20 (1), p.48-57

2012

Volltextzugriff (PDF)

Quantitative functional measures in MS: what is a reliable change?

Neurology, 2002-04, Vol.58 (8), p.1294-1296

2002

Volltextzugriff (PDF)

RGC-32 as a potential marker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

Journal of the neurological sciences, 2015-10, Vol.357, p.e17-e17

2015

Volltextzugriff (PDF)

Stem cell based delivery of IFN-β reduces relapses in experimental autoimmune encephalomyelitis

Journal of neuroimmunology, 2008-05, Vol.196 (1), p.67-81

2008

Volltextzugriff (PDF)

Hematopoietic Progenitors Express Neural Genes

Proceedings of the National Academy of Sciences - PNAS, 2003-12, Vol.100 (25), p.14926-14931

2003

Volltextzugriff (PDF)

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial

Neurology, 1994-06, Vol.44 (6), p.1054-1054

1994

Volltextzugriff (PDF)

Robot-Aided Neurorehabilitation: A Novel Robot for Ankle Rehabilitation

IEEE transactions on robotics, 2009-06, Vol.25 (3), p.569-582

2009

Volltextzugriff (PDF)

The cost of delaying treatment in multiple sclerosis: what is lost is not regained

Neurology, 2001-06, Vol.56 (12), p.1620-1620

2001

Volltextzugriff (PDF)

Invited article: Neurology and quality improvement: an introduction

Neurology, 2008-04, Vol.70 (18), p.1636-1640

2008

Volltextzugriff (PDF)

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

Neurology, 1996-06, Vol.46 (6), p.1639-1643

1996

Volltextzugriff (PDF)

The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study

Multiple sclerosis, 1995-11, Vol.1 (3), p.165-169

1995

Volltextzugriff (PDF)

Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle

Journal of neuroimmunology, 2009-05, Vol.210 (1), p.40-51

2009

Volltextzugriff (PDF)

The current status of studies of aminopyridines in patients with multiple sclerosis

Annals of neurology, 1994, Vol.36 (S1), p.S118-S121

Bever Jr, Christopher T.

1994

Volltextzugriff (PDF)

Increased cathepsin B activity in multiple sclerosis brain

Journal of the neurological sciences, 1995-07, Vol.131 (1), p.71-73

1995

Volltextzugriff (PDF)

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

Neurology, 1996-12, Vol.47 (6), p.1457-1462

1996

Volltextzugriff (PDF)

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Lancet neurology, 2008-10, Vol.7 (10), p.903-914

2008

Volltextzugriff (PDF)

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis: The EVIDENCE study

Journal of neurology, 2005, Vol.252 (1), p.8-13

2005

Volltextzugriff (PDF)

Performance of the dynamic single photon emission computed tomography (dSPECT) method for decreasing or increasing activity changes

Physics in medicine & biology, 2000-12, Vol.45 (12), p.3525-3543

2000

Volltextzugriff (PDF)

Glatiramer acetate blocks the activation of THP-1 cells by interferon- γ

European journal of pharmacology, 1998-01, Vol.342 (2), p.303-310

1998

Volltextzugriff (PDF)

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

Journal of neurology, neurosurgery and psychiatry, 2010-08, Vol.81 (8), p.907-912

2010

Volltextzugriff (PDF)

Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury?

Neurology, 1999-10, Vol.53 (7), p.1380-1380

1999

Volltextzugriff (PDF)

1 – 25 von 570

Suche als RSS-Feed

Suchergebnisse filtern

Filter anzeigen

Nur zeigen

Geprüft (Peer-Review)
(474)
Mit Volltextzugriff
(458)

Publikationsform

2 weitere anzeigen...

Weniger anzeigen...

Sprache

Erscheinungsjahr

n.n

Thema

Science & Technology
(340)
Life Sciences & Biomedicine
(289)
Humans
(251)
Female
(130)
Male
(119)
Biological And Medical Sciences
(109)
Medical Sciences
(85)
Adult
(84)
Neurosciences & Neurology
(69)
Animals
(55)
Middle Aged
(52)
Clinical Neurology
(49)
Genetics & Heredity
(46)
Child
(45)
Adolescent
(38)
Immunology
(37)
Neurology
(36)
Neurosciences
(36)
Fundamental And Applied Biological Sciences. Psychology
(33)
Pediatrics
(31)

15 weitere anzeigen...

Weniger anzeigen...

Neu hinzugefügt

Menü

Weitere Dienste

Einstellungen

Practice parameter: treatment of nervous system Lyme disease (an evidence-based review): report of the Quality Standards Subcommittee of the American Academy of Neurology

Quality improvement in neurology: AAN epilepsy quality measures: Report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology

Quality improvement in neurology: AAN Parkinson disease quality measures: report of the Quality Measurement and Reporting Subcommittee of the American Academy of Neurology

Changing Motor Synergies in Chronic Stroke

Learning, Not Adaptation, Characterizes Stroke Motor Recovery: Evidence From Kinematic Changes Induced by Robot-Assisted Therapy in Trained and Untrained Task in the Same Workspace

Quantitative functional measures in MS: what is a reliable change?

RGC-32 as a potential marker of relapse and response to treatment with glatiramer acetate in multiple sclerosis

Stem cell based delivery of IFN-β reduces relapses in experimental autoimmune encephalomyelitis

Hematopoietic Progenitors Express Neural Genes

The effects of 4-aminopyridine in multiple sclerosis patients: results of a randomized, placebo-controlled, double-blind, concentration-controlled, crossover trial

Robot-Aided Neurorehabilitation: A Novel Robot for Ankle Rehabilitation

The cost of delaying treatment in multiple sclerosis: what is lost is not regained

Invited article: Neurology and quality improvement: an introduction

Interferon beta-1b serum levels in multiple sclerosis patients following subcutaneous administration

The brief repeatable battery of neuropsychological tests for multiple sclerosis: a preliminary serial study

Brain-derived neurotrophic factor gene delivery in an animal model of multiple sclerosis using bone marrow stem cells as a vehicle

The current status of studies of aminopyridines in patients with multiple sclerosis

Increased cathepsin B activity in multiple sclerosis brain

Treatment with oral 3,4 diaminopyridine improves leg strength in multiple sclerosis patients: results of a randomized, double-blind, placebo-controlled, crossover trial

Comparison of subcutaneous interferon beta-1a with glatiramer acetate in patients with relapsing multiple sclerosis (the REbif vs Glatiramer Acetate in Relapsing MS Disease [REGARD] study): a multicentre, randomised, parallel, open-label trial

Comparative tolerance of IFN beta-1a regimens in patients with relapsing multiple sclerosis: The EVIDENCE study

Performance of the dynamic single photon emission computed tomography (dSPECT) method for decreasing or increasing activity changes

Glatiramer acetate blocks the activation of THP-1 cells by interferon- γ

Analysis of clinical outcomes according to original treatment groups 16 years after the pivotal IFNB-1b trial

Matrix metalloproteinases in multiple sclerosis: targets of therapy or markers of injury?

Suchergebnisse filtern